Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
2.23% $33.96
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 773.10 mill |
EPS: | -1.720 |
P/E: | -19.74 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 81.66 mill |
Avg Daily Volume: | 1.387 mill |
RATING 2024-03-27 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Neutral | |
P/E: | Strong Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -19.74 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-3.36x |
Company: PE -19.74 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 31.08 - 36.85 ( +/- 8.50%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Fmr Llc | Sell | 410 | Common Stock |
2024-02-13 | Fmr Llc | Sell | 1 155 | Common Stock |
2024-02-14 | Fmr Llc | Sell | 854 323 | Common Stock |
2024-02-14 | Fmr Llc | Sell | 45 677 | Common Stock |
2024-01-31 | Burrell Terry-ann | Buy | 55 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-29.02 |
Last 98 transactions |
Buy: 1 225 467 | Sell: 2 014 865 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $33.96 (2.23% ) |
Volume | 0.692 mill |
Avg. Vol. | 1.387 mill |
% of Avg. Vol | 49.89 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $28.15 | N/A | Active |
---|
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.